<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">avk</journal-id><journal-title-group><journal-title xml:lang="ru">Архивъ внутренней медицины</journal-title><trans-title-group xml:lang="en"><trans-title>The Russian Archives of Internal Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-6704</issn><issn pub-type="epub">2411-6564</issn><publisher><publisher-name>“SINAPS” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20514/2226-6704-2021-11-5-370-379</article-id><article-id custom-type="elpub" pub-id-type="custom">avk-1300</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>Роль уремической интоксикации в развитии  сердечно-сосудистого ремоделирования  у пациентов с хронической болезнью почек  3А-5Д стадий</article-title><trans-title-group xml:lang="en"><trans-title>The Role of Uremic Intoxication in the Development of Cardiovascular Remodeling in Patients with Chronic Kidney Disease Stages 3a-5d</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5856-0404</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гасанов</surname><given-names>М. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Gasanov</surname><given-names>M. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Митхат Зульфугарович Гасанов</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Mithat Z. Gasanov</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">mitkhat@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6905-6115</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коломыйцева</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolomyitseva</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Rostov-on-Don</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2733-4524</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Батюшин</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Batyushin</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Rostov-on-Don</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России, кафедра внутренних болезней № 1, кафедра внутренних болезней № 2</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University, Ministry of Health of Russian Federation, Department of the Internal Medicine № 1, Department of the Internal Medicine № 2</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>28</day><month>09</month><year>2021</year></pub-date><volume>11</volume><issue>5</issue><fpage>370</fpage><lpage>379</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гасанов М.З., Коломыйцева М.Н., Батюшин М.М., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Гасанов М.З., Коломыйцева М.Н., Батюшин М.М.</copyright-holder><copyright-holder xml:lang="en">Gasanov M.Z., Kolomyitseva M.N., Batyushin M.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medarhive.ru/jour/article/view/1300">https://www.medarhive.ru/jour/article/view/1300</self-uri><abstract><p>В последние десятилетия распространенность хронической болезни почек (ХБП) в популяции имеет отчетливую тенденцию к росту. Это связано, прежде всего, с увеличение м частоты встречаемости главных факторов, приводящих к ее развитию: сахарного диабета и артериальной гипертензии. Прогрессирование ХБП на фоне действия обозначенных факторов приводит к неуклонной потере почками их фильтрационной способности и развитию осложнений, связанных с этим процессом. К ним относятся, прежде всего, метаболические нарушения, расстройства кислотно-основного равновесия, дизэлектролитемии, уремическая интоксикация, гипергидратация, белково-энергетическая недостаточность, саркопения. Большинство из них участвует в развитии эндотелиальной дисфункции и формировании сердечно-сосудистого ремоделирования (ССР), как ключевого компонента кардиоренального континуума. При этом наблюдается взаимное негативное влияние патологии сердечно-сосудистой системы на функцию почек и проявлений ХБП на сердечно-сосудистую гемодинамику. Этот «порочный круг» приводит к развитию терминальной почечной недостаточности и повышению сердечно-сосудистого риска и смертности от болезней системы кровообращения пациентов на поздних стадиях ХБП. В связи с чем настоящая работа посвящена изучению роли уремической интоксикации и, в частности, индоксил сульфата, в развитии ССР у пациентов с ХБП на разных стадиях болезни. </p></abstract><trans-abstract xml:lang="en"><p>In recent decades, the prevalence of chronic kidney disease (CKD) in the population has a clear upward trend. This is due, first of all, to an increase in the frequency of occurrence of the main factors leading to its development: diabetes mellitus and arterial hypertension. The progression of CKD against the background of the action of these factors leads to a steady loss of the kidneys of their filtration capacity and the development of complications associated with this process. These include, first of all, metabolic and acid-base disorders, electrolyte abnormalities, uremic intoxication, overhydration, protein-energy wasting, sarcopenia and others. Most of them are involved in the development of endothelial dysfunction and the formation of cardiovascular remodeling (CVR), as a key component of the cardiorenal continuum. At the same time, there is a mutual negative influence of pathology of the cardiovascular system on renal function and manifestations of CKD on cardiovascular hemodynamics. This “vicious circle” leads to the development of end-stage renal disease and an increase in cardiovascular risk and mortality from diseases of the circulatory system in patients with advanced stages of CKD. In this connection, this work is devoted to the study of the role of uremic intoxication and, in particular, indoxyl sulfate, in the development of CVR in patients with CKD at different stages of the disease. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечно-сосудистое ремоделирование</kwd><kwd>кардиоренальный континуум</kwd><kwd>хроническая болезнь почек</kwd><kwd>индоксил сульфат</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cardiovascular remodeling</kwd><kwd>cardiorenal syndrome</kwd><kwd>chronic kidney disease</kwd><kwd>Indoxyl sulfate</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Арингазина А.М., Нарманова О.Ж., Нускабаева Г.О. и др. Хроническая болезнь почек: распространенность и факторы риска (обзор литературы). Анализ риска здоровью. 2020; 2: 164-174. doi: 10.21668/health.risk/2020.2.18.</mixed-citation><mixed-citation xml:lang="en">Aringazina A.M., Narmanova O.Zh., Nuskabaeva G.O. et al. Chronic kidney disease: prevalence and risk factors (literature review). Health Risk Analysis. 2020; 2: 164–174. doi: 10.21668/health.risk/2020.2.18. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Айдаров З.А., Жамилова Г.К., Юсупов А.Ф. и др. Хроническая почечная недостаточность и сердечно-сосудистые заболевания: проблема междисциплинарная. The Scientific Heritage. 2020; 49-2(49): 10-17.</mixed-citation><mixed-citation xml:lang="en">Aidarov Z., Zhamilova G., Yusupov A. et al. Chronic renal insufficiency and cardiovascular diseases: an interdisciplinary problem. The Scientific Heritage. 2020; 49-2(49): 10-17. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rakesh Malhotra, Ronit Katz, Vasantha Jotwani et al. Urine markers of kidney tubule cell injury and kidney function decline in SPRINT trial participants with CKD. Clin J Am Soc Nephrol. 2020; 15(3): 349-358. doi: 10.2215/CJN.02780319.</mixed-citation><mixed-citation xml:lang="en">Rakesh Malhotra, Ronit Katz, Vasantha Jotwani et al. Urine markers of kidney tubule cell injury and kidney function decline in SPRINT trial participants with CKD. Clin J Am Soc Nephrol. 2020; 15(3): 349-358. doi: 10.2215/CJN.02780319.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Батюшин М.М. Хроническая болезнь почек: современное состояние проблемы Рациональная фармакотерапия в кардиологии. 2020; 16(6): 938-947. doi:10.20996/1819-6446-2020-11-06.</mixed-citation><mixed-citation xml:lang="en">Batiushin M.M. Chronic Kidney Disease: Current State of the Problem. Rational Pharmacotherapy in Cardiology 2020; 16(6): 938-947. doi:10.20996/1819-6446-2020-11-06. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Муркамилов И.Т., Айтбаев К.А., Фомин В.В. и др. Факторы риска развития инсульта у пациентов с терминальной стадией хронической болезни почек: современное состояние проблемы. Казанский медицинский журнал. 2020; 101(6): 825-833.</mixed-citation><mixed-citation xml:lang="en">Murkamilov I.T., Aitbaev K.A., Fomin V.V. et al. Stroke risk factors in patients with end-stage kidney disease: current status of the problem. Kazan Medical Journal. 2020; 101(6): 825–833. doi: 10.17816/KMJ2020-825. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Цыганкова О.В., Худякова А.Д., Латынцева Л.Д. и др. Сердечнососудистый континуум: от факторов риска до систолической сердечной недостаточности. Атеросклероз. 2017; 13(4): 42-46.</mixed-citation><mixed-citation xml:lang="en">Tsygankova O.V., Khudyakova A.D., Latyntseva L.D. et al. Cаrdiovascular continuum: from risk factors to the systolic heart failure (the clinical case). Atherosclerosis. 2017; 13(4): 42-46. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Faiez Zannad, Patrick Rossignol. Cardiorenal Syndrome Revisited. Circulation. 2018; 138(9): 929-944. doi: 10.1161/circulationaha.117.028814.</mixed-citation><mixed-citation xml:lang="en">Faiez Zannad, Patrick Rossignol. Cardiorenal Syndrome Revisited. Circulation. 2018; 138(9): 929-944. doi: 10.1161/circulationaha.117.028814.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Левицкая Е.С., Батюшин М.М., Пасечник Д.Г. и др. Ремоделирование почечных артерий — инициатор и мишень кардиоренального континуума. Кардиоваскулярная терапия и профилактика. 2015; 14(1): 90-96. doi: http://dx.doi.org/10.15829/1728-8800- 2015-1-90-96.</mixed-citation><mixed-citation xml:lang="en">Levitskaya T.S., Batyushin М.М., Pasechnik D.G. et al. Renal arteries remodelling — the initiator and target of cardiorenal continuum. Cardiovascular Therapy and Prevention. 2015;14(1):90–96. doi: http://dx.doi.org/10.15829/1728-8800-2015-1-90-96. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Flore Duranton, Gerald Cohen, Rita De Smet et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23(7):1258-70. doi: 10.1681/ASN.2011121175.</mixed-citation><mixed-citation xml:lang="en">Flore Duranton, Gerald Cohen, Rita De Smet et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23(7):1258-70. doi: 10.1681/ASN.2011121175.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao TAN, Xuesen CAO, Jianzhou ZOU et al. Indoxyl sulfate, a valuable biomarker in chronic kidney disease and dialysis. Hemodialysis International. 2017; 21: 161–167. doi:10.1111/hdi.12483.</mixed-citation><mixed-citation xml:lang="en">Xiao TAN, Xuesen CAO, Jianzhou ZOU et al. Indoxyl sulfate, a valuable biomarker in chronic kidney disease and dialysis. Hemodialysis International. 2017; 21: 161–167. doi:10.1111/hdi.12483.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Гасанов М.З. Саркопения у пациентов с хронической болезнью почек: распространенность, особенности патогенеза и клиническое значение. Нефрология. 2021; 25(1): 47-58. https://doi. org/10.36485/1561-6274-2021-25-1-47-58.</mixed-citation><mixed-citation xml:lang="en">Gasanov M.Z. Sarcopenia in patients with chronic kidney disease: prevalence, pathogenesis and clinical significance. Nephrology (SaintPetersburg). 2021; 25(1): 47-58. doi: https://doi.org/10.36485/1561- 6274-2021-25-1-47-58. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Takuya Wakamatsu, Suguru Yamamoto, Toru Ito et al. Indoxyl sulfate promotes macrophage IL-1 production by activating aryl hydrocarbon receptor/NF-/MAPK Cascades, but the NLRP3 inflammasome was not activated. Toxins (Basel). 2018; 10(3): 124. doi: 10.3390/toxins10030124.</mixed-citation><mixed-citation xml:lang="en">Takuya Wakamatsu, Suguru Yamamoto, Toru Ito et al. Indoxyl sulfate promotes macrophage IL-1 production by activating aryl hydrocarbon receptor/NF-/MAPK Cascades, but the NLRP3 inflammasome was not activated. Toxins (Basel). 2018; 10(3): 124. doi: 10.3390/toxins10030124.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Emiko Sato, Takefumi Mori, Eikan Mishima et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci Rep. 2016; 6: 36618. doi: 10.1038/srep36618.</mixed-citation><mixed-citation xml:lang="en">Emiko Sato, Takefumi Mori, Eikan Mishima et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci Rep. 2016; 6: 36618. doi: 10.1038/srep36618.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hideki Fujii, Kentaro Nakai, Masafumi Fukagawa. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial. 2011; 15(2): 125-8. doi: 10.1111/j.1744-9987.2010.00883.x.</mixed-citation><mixed-citation xml:lang="en">Hideki Fujii, Kentaro Nakai, Masafumi Fukagawa. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial. 2011; 15(2): 125-8. doi: 10.1111/j.1744-9987.2010.00883.x.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yiru Wu, Xue Han, Liyan Wang et al. Indoxyl sulfate promotes vascular smooth muscle cell calcification via the JNK/Pit-1 pathway. Ren Fail. 2016;38(10):1702-1710. doi: 10.3109/0886022X.201 6.1155397.</mixed-citation><mixed-citation xml:lang="en">Yiru Wu, Xue Han, Liyan Wang et al. Indoxyl sulfate promotes vascular smooth muscle cell calcification via the JNK/Pit-1 pathway. Ren Fail. 2016;38(10):1702-1710. doi: 10.3109/0886022X.201 6.1155397.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hénaut L, Mary A, Chillon JM et al. The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function. Toxins (Basel). 2018; 10(6): 218. doi:10.3390/toxins10060218.</mixed-citation><mixed-citation xml:lang="en">Hénaut L, Mary A, Chillon JM et al. The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function. Toxins (Basel). 2018; 10(6): 218. doi:10.3390/toxins10060218.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Самолюк М.О., Григорьева Н.Ю. Оценка эндотелиальной дисфункции и возможности ее коррекции на современном этапе у больных сердечно-сосудистыми заболеваниями. Кардиология. 2019; 59(3S): 4-9. doi: https://doi.org/10.18087/cardio.2524.</mixed-citation><mixed-citation xml:lang="en">Samolyuk M.O., Grigorieva N.Yu. Evaluation of endothelial dysfunction and the possibility of its correction at the present stage in patients with cardiovascular diseases. Cardiology. 2019; 59(3S): 4-9. doi: https://doi.org/10.18087/cardio.2524. [in Russian].</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
